99% 10mg/30mg Weight Loss Ly-3437943 Peptide Retatrutide CAS 2381089-83-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Freeze-Dried Powder
• Purity: >99%
• Model NO.: Frazer-Retatrutide
• Appearance: White Powder
• CAS No: 2023788-19-2
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1box
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Delivery Time: 7-10days
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200box/Month

Product Description

99% 10mg/30mg Weight Loss Ly-3437943 Peptide Retatrutide CAS 2381089-83-2

 

Description:

Product Name:	Retatrutide
CAS:	2381089-83-2
Shelf life:	24 months
Specification:	5mg x10vials /box
Appearance:	Lyophilized powder

 

1. Treatment of depression and anxiety disorders: Retatrutide has been shown to have antidepressant and anxiolytic effects in preclinical studies, suggesting that it could be a promising treatment option for individuals with these conditions.
2. Prevention of neurodegenerative diseases: Retatrutide has neuroprotective properties that may be useful in preventing or slowing the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's.
3. Enhancement of cognitive function: Retatrutide has been shown to improve learning and memory in animal studies, suggesting that it could have potential as a cognitive enhancer in humans.
4. Treatment of chronic pain: Retatrutide has been shown to have analgesic effects in preclinical studies, suggesting that it could be a useful treatment option for individuals with chronic pain conditions.
5. Promotion of wound healing: Retatrutide has been shown to accelerate wound healing in animal studies, suggesting that it could have potential as a therapeutic agent for promoting wound healing in humans.

Uses:
Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.

•